Search

TG Therapeutics Inc

Закрыт

СекторЗдравоохранение

55.79 -1.24

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

55.66

Макс.

56.25

Ключевые показатели

By Trading Economics

Доход

7.8M

28M

Продажи

35M

240M

P/E

Средняя по отрасли

19.818

56.659

Прибыль на акцию

0.05

Рентабельность продаж

11.466

Сотрудники

399

EBITDA

-6.4M

22M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+23.56% upside

Дивиденды

By Acuity

Следующий отчет о доходах

2 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.2B

8.3B

Предыдущая цена открытия

57.03

Предыдущая цена закрытия

55.79

Новостные настроения

By Acuity

50%

50%

132 / 339 Рейтинг в Healthcare

TG Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 сент. 2026 г., 20:07 UTC

Social Media

TG Therapeutics Inc is declining amid increased selling pressure in risk assets following a strong jobs report raising monetary policy concerns.

3 сент. 2026 г., 20:07 UTC

News
Social Media

TG Therapeutics will participate in the Cantor Global Healthcare Conference. Shares are lower today, despite earlier gains and positive sentiment surrounding the company.

2 сент. 2026 г., 20:02 UTC

Social Media

TG Therapeutics shares are higher as HC Wainwright reiterates its Buy rating. Social media valuations suggest a price range of $78 to $85 per share.

1 сент. 2026 г., 19:54 UTC

News
Social Media

TG Therapeutics shares are rising as H.C. Wainwright maintains a Buy rating and sets a price target of $78, indicating significant upside potential.

31 авг. 2026 г., 22:16 UTC

TG Therapeutics Inc. shares showed little change in after-market trading. The stock remains above its 20-day moving average, indicating stability.

28 авг. 2026 г., 19:51 UTC

TG Therapeutics Inc shares are lower today, continuing a decline since Thursday's close. The stock remains above its 20-day moving average.

27 авг. 2026 г., 23:41 UTC

TG Therapeutics Inc shares are lower in after-market hours, reflecting broader market declines. Economic indicators have not alleviated cautious sentiment amid inflation concerns.

26 авг. 2026 г., 19:16 UTC

Social Media
News

TG Therapeutics raised its Briumvi revenue guidance to $890-$905 million, contributing to an upgrade of TGTX stock. Shares are trading roughly flat today.

25 авг. 2026 г., 23:36 UTC

TG Therapeutics Inc. shares are trading roughly flat in after-market hours. The stock remains above its 20-day moving average and near its one-month trading range.

24 авг. 2026 г., 23:21 UTC

TG Therapeutics Inc shares are higher in after-market hours, reflecting positive momentum following Monday's close, despite no specific news driving the movement.

22 авг. 2026 г., 00:02 UTC

Social Media

TG Therapeutics shares are higher in after-market trading amid positive investor sentiment and discussions of significant price targets of $150 following recent market pressures.

21 авг. 2026 г., 23:01 UTC

Social Media

TG Therapeutics Inc. is rising in after-market trading, fueled by positive investor sentiment and potential price targets between $150 and $200.

20 авг. 2026 г., 21:01 UTC

TG Therapeutics Inc shares are higher in after-market hours, despite earlier declines. No specific news was identified to explain the price movement.

19 авг. 2026 г., 19:27 UTC

TG Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday. The stock is trading above its 20-day moving average.

17 авг. 2026 г., 19:56 UTC

Social Media
News

TG Therapeutics reported Q2 2026 revenue of $240.34 million and raised its full-year outlook to $950 million, driving shares higher during Monday's trading.

14 авг. 2026 г., 21:01 UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

13 авг. 2026 г., 20:02 UTC

Social Media

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

10 авг. 2026 г., 19:16 UTC

TG Therapeutics Inc shares are lower today amid a broader market decline, with U.S. stock futures dropping following a surprising labor market report.

7 авг. 2026 г., 23:16 UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

6 авг. 2026 г., 20:03 UTC

News

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

5 авг. 2026 г., 19:56 UTC

Social Media

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

4 авг. 2026 г., 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

3 авг. 2026 г., 23:06 UTC

Social Media

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.

31 июл. 2026 г., 23:16 UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30 июл. 2026 г., 23:56 UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29 июл. 2026 г., 15:52 UTC

Social Media
News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28 июл. 2026 г., 19:56 UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27 июл. 2026 г., 19:07 UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24 июл. 2026 г., 23:21 UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23 июл. 2026 г., 23:22 UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

Сравнение c конкурентами

Изменение цены

TG Therapeutics Inc Прогноз

Целевая цена

By TipRanks

23.56% рост

Прогноз на 12 месяцев

Средняя 69.17 USD  23.56%

Максимум 86 USD

Минимум 21 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для TG Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

6 ratings

5

Покупка

0

Удержание

1

Продажа

Настроения

By Acuity

132 / 339Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat